Researchers at The University of Manchester have discovered that a potential new drug reduces the number of brain cells destroyed by stroke and then helps to repair the damage.
A reduction in blood flow to the brain caused by stroke is a major cause of death and disability, and there are few effective treatments.
A team of scientists at The University of Manchester has now found that a potential new stroke drug not only works in rodents by limiting the death of existing brain cells but also by promoting the birth of new neurones (so-called neurogenesis).
This finding provides further support for the development of this anti-inflammatory drug, interleukin-1 receptor antagonist (IL-1Ra in short), as a new treatment for stroke. The drug is already licensed for use in humans for some conditions, including rheumatoid arthritis. Several early stage clinical trials in stroke with IL-1Ra have already been completed in Manchester, though it is not yet licensed for this condition.
In the research, published in the biomedical journal Brain, Behavior and Immunity, the researchers show that in rodents with a stroke there is not only reduced brain damage early on after the stroke, but several days later increased numbers of new neurones, when treated with the anti-inflammatory drug IL-1Ra.
Previous attempts to find a drug to prevent brain damage after stroke have proved unsuccessful and this new research offers the possibility of a new treatment.
Importantly, the use of IL-1Ra might be better than other failed drugs in stroke as it not only limits the initial damage to brain cells, but also helps the brain repair itself long-term through the generation of new brain cells.
The results lend further strong support to the use of IL-1Ra in the treatment of stroke, however further large trials are necessaryProfessor Stuart Allan
These new cells are thought to help restore function to areas of the brain damaged by the stroke. Earlier work by the same group showed that treatment with IL-1Ra does indeed help rodents regain motor skills that were initially lost after a stroke. Early stage clinical trials in stroke patients also suggest that IL-1Ra could be beneficial.
The Latest on: Stroke treatment
via Google News
The Latest on: Stroke treatment
- Colchicine cuts odds of new heart attack, stroke in heart attack survivorson November 18, 2019 at 11:50 am
(Reuters Health) - The inflammation-fighting drug colchicine, already a treatment for gout, dramatically reduces the odds of future cardiovascular problems in people who have just survived a heart ...
- Lower LDL Target Better After Strokeon November 18, 2019 at 11:49 am
Overall, 86% of the patients had proven ischemic stroke on MRI. In the lower target group, ezetimibe (Zetia) was added to statin treatment in 33%, compared with 5% in the higher target group. Patients ...
- Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trialon November 18, 2019 at 11:02 am
PHILADELPHIA, PA—Prescribing statins to achieve a more aggressive LDL treatment target in patients who have had a TIA or ischemic stroke of atherosclerotic origins reduces the risk of major ...
- 15-year study finds treatment gaps exist for patients with peripheral arterial diseaseon November 18, 2019 at 12:12 am
From 1999 through 2013, a statin prescription increased in five-year increments from 17% to 37% to 48%, indicating steady progress toward the 100% ultimate treatment goal. However, the most recent ...
- Napa’s NeuroSpring develops new medical treatments for stroke patientson November 16, 2019 at 3:00 pm
“We’re trying to learn about something we don’t already know about,” said Ballesteros. By studying the rats’ brains, he hopes to determine if a NeuroSpring treatment can affect the animal’s brain when ...
- Treatment to ward off stroke less effective in womenon November 15, 2019 at 5:54 am
a key risk factor for stroke. "Men and women are different and sometimes their disease might call for a different treatment approach," said the study's lead investigator Niveditta Ramkumar, a graduate ...
- Stroke among cancer patientson November 15, 2019 at 2:22 am
Our work has limitations. The overall number of deaths from stroke was relatively limited overall (1% of cancer patients), and more detailed analyses on risk factors could not be performed. Treatment ...
- Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market to Witness Huge Growth by 2026: Evaluating By Global Leading Playerson November 13, 2019 at 10:05 pm
Nov 14, 2019 (Market Prediction via COMTEX) -- A new research report titled “Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market” successfully exhibits the complete scenario of the ...
- New Results: Brainomix Software Shown to Improve Stroke Treatment Rates at Budapest University Hospitalon November 13, 2019 at 4:09 pm
Results Showed e-Stroke Suite Associated with Increase in Thrombolysis and Thrombectomy Treatment Rates for Stroke Patients OXFORD, England, Nov. 12, 2019 /PRNewswire/ -- Last Friday during a ...
via Bing News